Health technology agency insights: informing modification of a qualitative benefit risk framework for health technology reassessment of prescription medications

16 September 2019 - This study's intent was to determine if a qualitative benefit risk framework could be used or modified ...

Read more →

As value assessment frameworks evolve, are they finally ready for prime time?

9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...

Read more →

ICER Proposes Updates to 2020 Value Assessment Framework Methods and Procedures

21 August 2019 - Reflecting experience with current framework, benchmarking with other HTA groups, and public input, proposals include new emphasis ...

Read more →

ICER's value framework and patient feedback: Q&A with Steve Pearson

15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...

Read more →

Novel approaches to value assessment within the cost-effectiveness framework

20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions ...

Read more →

Framework for the regulation of regenerative medicine products

21 May 2019 - The U.S. FDA has published four final guidance documents that are part of a comprehensive policy framework ...

Read more →

ICER seeks public input for 2020 value assessment framework

2 May 2019 - Accepting Open Input Through 10 June 2019. ...

Read more →

Comparative assessment of clinical benefit using the ESMO Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score

19 December 2018 - To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) ...

Read more →

The use of MCDA in HTA: great potential, but more effort needed

18 April 2018 - The potential for multi-criteria decision analysis (MCDA) to support health technology assessment (HTA) has been much discussed, ...

Read more →

Decision components of NICE's technology appraisals assessment framework

10 April 2018 - The UK's NICE is an established health technology assessment agency. de Folter et al. present a ...

Read more →

A health economics approach to US value frameworks: serving the needs of decision-making

22 February 2018 - Value assessment is an integral component of decision making in health and is the focus of a ...

Read more →

Patient-centered decision making: lessons from multi-criteria decision analysis for quantifying patient preferences

26 December 2018 - Patient preferences should be a central consideration in healthcare decision making.  ...

Read more →

Statement from FDA Commissioner on FDA’s comprehensive new policy approach to facilitating the development of innovative regenerative medicine products to improve human health

16 November 2017 - One of the most promising fields of science is the area of cell-based therapies and their ...

Read more →

Institute for Clinical and Economic Review announces final modified framework for assessing value of treatments for ultra rare diseases

13 November 2017 - Broader societal considerations and expanded cost-effectiveness ranges will be included for treatments targeting fewer than 10,000 patients. ...

Read more →

Social value and individual choice: the value of a choice-based decision-making process in a collectively funded health system

4 October 2017 - Evidence about cost-effectiveness is increasingly being used to inform decisions about the funding of new technologies that ...

Read more →